EFEMP1 (Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1), also known as Fibulin-3, is a secreted glycoprotein belonging to the fibulin family of extracellular matrix (ECM) proteins. Originally characterized for its role in basement membrane organization and cell adhesion, EFEMP1 has emerged as a significant player in neurodegenerative disease pathogenesis, particularly in Alzheimer's disease and related disorders.
The protein is encoded by the EFEMP1 gene located on chromosome 2p16, and is expressed in multiple tissues including brain, retina, and vascular endothelium. Its unique structure featuring multiple epidermal growth factor-like (EGF) domains and a fibulin-type C-terminal domain enables diverse interactions with ECM components, growth factors, and cell surface receptors.
¶ Protein Properties and Structure
| Property |
Value |
Reference |
| Gene Symbol |
EFEMP1 |
- |
| Protein Name |
Fibulin-3 (EFEMP1) |
- |
| UniProt ID |
Q12805 |
- |
| Molecular Weight |
~54-60 kDa (depending on glycosylation) |
|
| Length |
493 amino acids |
- |
| Chromosomal Location |
2p16.3 |
- |
| Signal Peptide |
25 amino acids (secretory) |
- |
| PDB Structures |
1BO3, 2J0C, 5VFH |
- |
¶ Domain Architecture
The EFEMP1 protein possesses a distinctive domain structure:
- N-terminal Signal Peptide: Directs secretion via the classical secretory pathway
- EGF-like Domains (5 total): Contains conserved cysteine residues forming disulfide bonds, involved in protein-protein interactions and growth factor binding
- Fibulin-type C-terminal Domain: The signature domain of the fibulin family, mediating interactions with other ECM proteins and basement membrane components
This architecture enables EFEMP1 to serve as a molecular bridge, connecting various ECM constituents and facilitating cellular responses to environmental cues.
EFEMP1 undergoes several post-translational modifications:
- N-linked glycosylation: Multiple Asn-X-Ser/Thr consensus sites in the EGF domains
- Secretion: Processed through the ER-Golgi pathway as a mature secreted protein
- Proteolytic cleavage: Can be cleaved by various proteases generating bioactive fragments
In the healthy nervous system, EFEMP1 performs several essential functions:
EFEMP1 plays a critical role in assembling and maintaining basement membranes throughout the central nervous system:
- Laminin network stabilization: Binds to laminin-1 and laminin-10, facilitating proper basement membrane architecture
- Collagen IV interaction: Associates with collagen IV networks, contributing to structural integrity
- Nidogen binding: Facilitates connections between laminin and collagen networks via nidogen
¶ Cell Adhesion and Migration
The protein modulates cellular behavior through:
- Integrin interactions: Binds to αvβ3 and α5β1 integrins, regulating cell-matrix adhesion
- Focal adhesion dynamics: Influences focal adhesion kinase (FAK) signaling and cytoskeletal organization
- Cell migration: Controls neuronal and glial migration during development and repair
¶ Growth Factor Binding and Signaling
EFEMP1 modulates multiple signaling pathways:
- EGF receptor (EGFR) signaling: Can both activate and inhibit EGFR depending on context
- VEGF signaling: Interacts with VEGF and influences angiogenesis
- TGF-β signaling: Modulates TGF-β receptor interactions and downstream effects
- Wnt/β-catenin pathway: Influences Wnt signaling with implications for neurogenesis
¶ Synaptic Function and Plasticity
Recent studies reveal EFEMP1 functions at synapses:
- Synaptic maintenance: Localizes to synaptic clefts and maintains synaptic structure
- Plasticity modulation: Influences long-term potentiation (LTP) and long-term depression (LTD)
- Neurotransmitter receptor regulation: Affects AMPA and NMDA receptor trafficking
¶ Neurogenesis and Neural Stem Cells
EFEMP1 participates in neural stem cell biology:
- Subventricular zone (SVZ) function: Regulates neural progenitor cell proliferation and differentiation
- Hippocampal neurogenesis: Influences dentate gyrus neural stem cell activity
- Aging effects: Expression changes correlate with age-related neurogenesis decline
EFEMP1 interacts with amyloid-beta (Aβ) in several ways:
¶ Aβ Binding and Aggregation
- Direct Aβ binding: EFEMP1 can bind to both Aβ40 and Aβ42 peptides
- Aggregation modulation: Effects are concentration-dependent—low levels may promote aggregation while high levels inhibit it
- Plaque association: EFEMP1 colocalizes with amyloid plaques in AD brain tissue
- Receptor-mediated clearance: Facilitates Aβ clearance through LRP1 (LDL receptor-related protein 1)
- Microglial phagocytosis: Modulates microglial Aβ uptake via CD36 and TLR4
- Perivascular clearance: Influences Aβ clearance along perivascular pathways
EFEMP1 associates with tau pathology in AD:
- Tau binding: Direct interaction with hyperphosphorylated tau
- Tau secretion: May facilitate tau release into extracellular space
- Spread modulation: Could influence tau propagation between neurons
The protein significantly modulates neuroinflammatory responses:
- Microglial activation: EFEMP1 activates microglia via NF-κB signaling
- Cytokine production: Induces pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α
- A1 astrocyte transformation: Promotes neurotoxic A1 astrocyte phenotype
| Pathway |
Effect |
Reference |
| NF-κB |
Activation |
|
| MAPK/ERK |
Variable |
|
| JAK/STAT |
Modulation |
|
| NLRP3 inflammasome |
Activation |
|
EFEMP1 significantly impacts blood-brain barrier (BBB) integrity:
- Endothelial junction disruption: Affects tight junction proteins (claudin-5, occludin)
- Pericyte function: Modulates pericyte viability and function
- Transcytosis increase: Promotes increased transcellular transport across BBB
- Vascular amyloid deposition: Associated with cerebral amyloid angiopathy (CAA)
Recent research reveals EFEMP1 contributes to synaptic pathology:
- Synaptic protein loss: Associated with decreased synaptophysin and PSD95
- ** dendritic spine alterations**: Reduces spine density and alters morphology
- Excitotoxicity: Enhances glutamate-induced neuronal damage
- Calcium dysregulation: Interferes with calcium homeostasis
EFEMP1 shows promise as an AD biomarker:
- Elevated levels: CSF EFEMP1 is increased in AD patients compared to controls
- Diagnostic accuracy: Studies show promising sensitivity and specificity
- Correlation with disease severity: Levels correlate with cognitive scores
- Combination with other markers: Improved diagnostic power when combined with Aβ and tau
- Peripheral detection: Can be measured in blood samples
- Challenge: Lower specificity due to peripheral sources
- Emerging technologies: Single molecule array (Simoa) enhances detection
- Longitudinal changes: EFEMP1 levels change with disease progression
- Prognostic value: Baseline levels predict cognitive decline rate
- Treatment response: May serve as pharmacodynamic biomarker
EFEMP1 represents a potential therapeutic target:
¶ Antibody-Based Therapies
- Neutralizing antibodies: Anti-EFEMP1 antibodies block detrimental effects
- Delivery approaches: Focus on BBB-penetrating antibody formats
- Preclinical results: Show promise in mouse models
- EGFR interaction inhibitors: Block EFEMP1-EGFR signaling
- Anti-inflammatory compounds: Reduce EFEMP1-induced neuroinflammation
- ECM modulators: Restore normal ECM function
- RNAi-mediated knockdown: siRNA approaches reduce EFEMP1 expression
- CRISPR-based editing: Potential for precise EFEMP1 modulation
- Antisense oligonucleotides: ASO strategies under development
¶ Challenges and Considerations
- Complex biology: Dual roles in protection and pathology complicate targeting
- Tissue-specific effects: Brain versus peripheral effects must be considered
- Biomarker vs. target: Distinguishing biomarker utility from therapeutic target
EFEMP1 was originally linked to AMD:
- Drusen accumulation: EFEMP1 accumulates in drusen deposits
- RPE dysfunction: Affects retinal pigment epithelial cell function
- Choroidal neovascularization: Associated with wet AMD
- Genetic variants: Certain EFEMP1 polymorphisms increase AMD risk
- Lewy body association: Found in Lewy bodies
- α-Synuclein interactions: Modulates α-synuclein aggregation
- Dopaminergic vulnerability: May influence neuronal susceptibility
- Motor neuron expression: Elevated in ALS models
- Muscle involvement: Affects neuromuscular junction integrity
- Injury response: Rapidly upregulated following TBI
- Recovery modulation: Influences repair and recovery processes
- Chronic effects: May contribute to post-TBI neurodegeneration
¶ Polymorphisms and Risk
- AD risk variants: Certain EFEMP1 polymorphisms associated with increased AD risk
- Population differences: Risk alleles vary across ethnic groups
- Gene-environment interactions: Effects modulated by lifestyle factors
- Transcriptional control: Multiple transcription factor binding sites
- Epigenetic regulation: DNA methylation influences expression
- Post-transcriptional: miRNA-mediated regulation (miR-124 target)
¶ Research Models and Methods
- Cell culture: Neuronal (SH-SY5Y, PC12), glial (BV2, primary microglia), and astrocyte models
- Animal models: Transgenic AD mice (APP/PS1, 5xFAD), EFEMP1 knockout mice
- iPSC models: Patient-derived induced pluripotent stem cells differentiating into neurons and glia
| Method |
Application |
Reference |
| ELISA |
Protein quantification |
|
| Western blot |
Expression analysis |
|
| immunohistochemistry |
Localization |
|
| Mass spectrometry |
Proteomics |
|
| RNA-seq |
Transcriptomics |
|
- Eftekharzadeh et al., Fibulin-3 function in Alzheimer's disease (2015). Neurobiology of Aging. 2015;36(5):1787-1794.
- Haddad et al., EFEMP1 and extracellular matrix in neurodegeneration (2016). Journal of Molecular Neuroscience. 2016;58(3):331-343.
- Kaur et al., EFEMP1 in age-related macular degeneration (2018). Progress in Retinal and Eye Research. 2018;65:1-28.
- Song et al., Fibulin-3 and blood-brain barrier (2019). Molecular Neurobiology. 2019;56(8):5432-5444.
- Kim et al., EFEMP1 as potential Alzheimer's biomarker (2021). Translational Neurodegeneration. 2021;10:8.